Monitor for future real-world data readouts or regulatory updates from the Early Access Program, which could inform the Phase 3 trial trajectory and commercial potential. Given the lack of approved FAP therapies, successful outcomes could position eRapa as a first-in-class treatment, though near-term revenue impact is unlikely.
Price Chart
Executive Summary
Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a global Early Access Program for its investigational drug eRapa in patients with Familial Adenomatous Polyposis (FAP), a rare genetic disorder with no approved therapies. The program allows clinicians to prescribe eRapa outside clinical trials, while Biodexa collects real-world data to support development. This expands access to a novel mTOR inhibitor with orphan designation in the U.S. and ongoing Phase 3 development.
Key Facts
- Biodexa launched a global Early Access Program for eRapa in FAP patients via partnership with Tanner Pharma Group.
- eRapa is an investigational oral mTOR inhibitor with U.S. Orphan Drug Designation; European designation planned.
- The program enables prescription outside clinical trials, subject to local regulations and funding.
- Biodexa will collect real-world data to support understanding of FAP and drug use.
- Phase 3 trial for eRapa is planned for 168 patients across 30 sites in the U.S. and Europe, supported by a $20M CPRIT grant.
- FAP has no approved pharmacologic treatment; standard of care remains surgery.
Financial Impact
No immediate financial impact disclosed; potential future revenue from expanded access and real-world use, but no pricing or sales figures provided.
Risk Factors
- eRapa remains investigational; no guarantee of regulatory approval or commercial success.
- Early Access Programs do not generate significant revenue and may expose the company to safety or liability risks.
- Biodexa has a small market cap ($2M), indicating high risk and potential illiquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260365 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 6-K | $0.4849 | awaiting T+20 | — | — |
Oct 8, 2026 18d ago | 6-K | $0.4602 | awaiting T+20 | — | — |
Oct 1, 2026 25d ago | EFFECT | $0.6326 | awaiting T+20 | — | — |
Sep 24, 2026 4w ago | F-1 | $0.6750 $0.4140 | ▲ +38.67% | ▲ +38.25% | — |
Sep 15, 2026 5w ago | 6-K | $1.33 $0.3502 | ▼ −73.67% | ▼ −76.65% | — |
Sep 11, 2026 6w ago | 6-K | $1.12 $0.3832 | ▲ +65.79% | ▲ +68.05% | — |
Aug 4, 2026 11w ago | EFFECT | $1.49 $0.7808 | ▲ +47.60% | ▲ +46.36% | — |
Jun 30, 2026 16w ago | 6-K | $3.00 $1.45 | ▼ −51.83% | ▼ −49.65% | — |
Jun 30, 2026 16w ago | 6-K | $2.91 $1.45 | ▲ +50.34% | ▲ +48.03% | — |
Jun 17, 2026 18w ago | 6-K | $3.06 $2.13 | ▼ −30.39% | ▼ −30.93% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers